William Rote Sells 2,763 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Key Points

• Insider William Rote sold 2,763 shares of Travere Therapeutics at an average price of $43.95 on May 6 under a pre‑arranged Rule 10b5‑1 trading plan, reducing his stake by about 2.34% per the SEC filing.
• Travere beat Q1 expectations with an EPS beat of $0.05 vs. a ($0.24) estimate and revenue of $127.2 million (up 55.6% year‑over‑year), though the company still reported a negative net margin.
• Analyst sentiment is broadly positive with multiple firms raising price targets (e.g., TD Cowen to $60) and major institutional investors like Vanguard and State Street materially increasing their holdings.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider William Rote sold 2,763 shares of Travere Therapeutics stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $121,433.85. Following the completion of the transaction, the insider owned 115,474 shares of the company's stock, valued at approximately $5,075,082.30. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 0.2%

TVTX traded down $0.10 on Wednesday, hitting $44.70. The company had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The company has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $48.61. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16. The business's fifty day simple moving average is $32.59 and its 200 day simple moving average is $32.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.29. The company had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm's revenue was up 55.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) earnings per share. Equities research analysts expect that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Travere Therapeutics by 10.3% during the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock valued at $158,059,000 after buying an additional 619,085 shares during the period. State Street Corp boosted its position in shares of Travere Therapeutics by 47.8% during the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after buying an additional 1,538,827 shares during the period. Perceptive Advisors LLC boosted its position in shares of Travere Therapeutics by 12.7% during the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock valued at $163,469,000 after buying an additional 483,565 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Travere Therapeutics by 27.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock valued at $41,203,000 after buying an additional 599,102 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Travere Therapeutics by 28.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock valued at $85,849,000 after buying an additional 494,665 shares during the period.

Analyst Ratings Changes

TVTX has been the subject of several recent research reports. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday, April 14th. TD Cowen lifted their price target on Travere Therapeutics from $45.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday. HC Wainwright lifted their price target on Travere Therapeutics from $47.00 to $57.00 and gave the stock a "buy" rating in a research report on Tuesday. Guggenheim lifted their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, April 24th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.83.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.